Loading...
XLONAZN
Market cap428bUSD
Jan 24, Last price  
11,050.00GBP
1D
0.04%
1Q
-4.79%
Jan 2017
149.01%
IPO
353.43%
Name

AstraZeneca PLC

Chart & Performance

D1W1MN
XLON:AZN chart
P/E
7,184.68
P/S
933.94
EPS
1.92
Div Yield, %
1.67%
Shrs. gr., 5y
4.28%
Rev. gr., 5y
15.71%
Revenues
45.81b
+3.29%
21,426,000,00023,950,000,00026,475,000,00029,559,000,00031,601,000,00032,804,000,00033,269,000,00033,591,000,00027,973,000,00025,711,000,00026,095,000,00024,708,000,00023,002,000,00022,465,000,00022,090,000,00024,384,000,00026,617,000,00037,417,000,00044,351,000,00045,811,000,000
Net income
5.96b
+81.11%
3,664,000,0004,706,000,0006,043,000,0005,595,000,0006,101,000,0007,521,000,0008,053,000,0009,983,000,0006,297,000,0002,556,000,0001,233,000,0002,825,000,0003,499,000,0003,001,000,0002,155,000,0001,335,000,0003,196,000,000112,000,0003,288,000,0005,955,000,000
CFO
10.35b
+5.48%
4,873,000,0006,743,000,0007,693,000,0007,510,000,0008,742,000,00011,739,000,00010,680,000,0007,821,000,0006,948,000,0007,400,000,0007,058,000,0003,324,000,0004,145,000,0003,578,000,0002,618,000,0002,969,000,0004,799,000,0005,963,000,0009,808,000,00010,345,000,000
Dividend
Aug 08, 202460.81512 GBP/sh
Earnings
Feb 06, 2025

Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
URL
https://www.astrazeneca.com/
IPO date
Sep 21, 2007
Employees
83,500
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
45,811,000
3.29%
44,351,000
18.53%
Cost of revenue
37,000,000
41,108,000
Unusual Expense (Income)
NOPBT
8,811,000
3,243,000
NOPBT Margin
19.23%
7.31%
Operating Taxes
938,000
(792,000)
Tax Rate
10.65%
NOPAT
7,873,000
4,035,000
Net income
5,955,000
81.11%
3,288,000
2,835.71%
Dividends
(4,481,000)
(4,364,000)
Dividend yield
1.06%
1.03%
Proceeds from repurchase of equity
33,000
(891,000)
BB yield
-0.01%
0.21%
Debt
Debt current
6,389,000
5,542,000
Long-term debt
24,350,000
24,643,000
Deferred revenue
7,000
14,000
Other long-term liabilities
5,338,000
6,484,000
Net debt
23,102,000
22,877,000
Cash flow
Cash from operating activities
10,345,000
9,808,000
CAPEX
(1,361,000)
(2,571,000)
Cash from investing activities
(4,064,000)
(2,960,000)
Cash from financing activities
(6,567,000)
(6,823,000)
FCF
12,180,000
(603,000)
Balance
Cash
5,860,000
6,405,000
Long term investments
1,777,000
903,000
Excess cash
5,346,450
5,090,450
Stockholders' equity
3,978,000
1,455,000
Invested Capital
70,144,000
70,437,000
ROIC
11.20%
5.59%
ROCE
11.45%
4.33%
EV
Common stock shares outstanding
3,124,000
3,120,000
Price
134.70
-0.66%
135.60
16.39%
Market cap
420,802,800
-0.54%
423,072,000
27.24%
EV
443,927,800
445,970,000
EBITDA
13,745,000
8,723,000
EV/EBITDA
32.30
51.13
Interest
1,589,000
1,346,000
Interest/NOPBT
18.03%
41.50%